Mineralys Therapeutics (MLYS) Long-Term Investments (2023)

Mineralys Therapeutics (MLYS) reported Long-Term Investments of $2.5 million for Q4 2023, down 79.54% sequentially from $12.1 million in Q3 2023.

Mineralys Therapeutics (MLYS) Long-Term Investments (2023) Analysis & Trends

Mineralys Therapeutics (MLYS) has 1 years of Long-Term Investments data on file, last reported at $2.5 million in Q4 2023.

For the quarter ending Q4 2023, Long-Term Investments changed N/A year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2023 stood at $2.5 million (changed N/A YoY), and the FY2023 full-year result was $2.5 million, changed N/A from the prior year.
Long-Term Investments declined to $2.5 million in Q4 2023, from $12.1 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $31.1 million in Q1 2023 to a low of $2.5 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Mineralys Therapeutics	2.24 Bn	2.24 Bn	-	-

Download Data